Medscape Clinical Trend: Metformin⁠

 | Post date: 2020/09/1 | 
Medscape Clinical Trend: Metformin⁠⠀
The most commonly prescribed drug for #type2 #diabetes may be associated with reduced risk for death due to COVID-19. ⁠⠀
The latest results, which are not yet peer reviewed, were recently published online and show a significant reduction in mortality in patients with diabetes and COVID-19 who used #metformin. ⁠⠀
These findings support the results of four previous studies that also showed a reduction in mortality among metformin users compared with nonusers. ⁠⠀
However, experts say that the randomized controlled trials needed to conclusively prove this benefit are "almost impossible in the context of COVID-19."⁠⠀
Metformin has been in the news this week for other reasons as well. Tap the link in our bio to read further study analysis.⁠

Keywords: coronavirus | covid19 |

View: 481 Time(s)   |   Print: 176 Time(s)   |   Email: 0 Time(s)   |   0 Comment(s)

© 2022 All Rights Reserved | Iranian Society of Pathology

Designed & Developed by : Yektaweb